Cargando…
Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19
The ongoing COVID-19 pandemic has infected nearly 3,582,233 individuals with 248,558 deaths since it was first identified in human populations in December 2019 in Wuhan, China. No antiviral therapies or vaccines are available for their treatment or prevention. Passive immunization PI through broadly...
Autores principales: | Alzoughool, Foad, Alanagreh, Lo’ai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306893/ https://www.ncbi.nlm.nih.gov/pubmed/32310190 http://dx.doi.org/10.3233/JRS-201017 |
Ejemplares similares
-
Risk of using hydroxychloroquine as a treatment of COVID-19
por: Alanagreh, Lo’ai, et al.
Publicado: (2020) -
The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms
por: Alanagreh, Lo’ai, et al.
Publicado: (2020) -
Associations of pre-existing cardiovascular morbidity with severity and the fatality rate in COVID-19 patients: a systematic review and meta-analysis
por: Alzoughool, Foad, et al.
Publicado: (2022) -
The optimal therapeutic irisin dose intervention in animal model: A systematic review
por: Alzoughool, Foad, et al.
Publicado: (2020) -
New SARS-CoV-2 Variant from Jordan
por: Alanagreh, Lo’ai, et al.
Publicado: (2021)